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Received 1 Nov 2019; first review completed 19 Nov 2019; accepted in final form 4 Dec 2019ABSTRACT—Trauma, burn injury, sepsis, and ischemia lead to acute and chronic loss of skeletal musclemass and function.
Healthy muscle is essential for eating, posture, respiration, reproduction, and mobility, as well as for appropriate function of
the senses including taste, vision, and hearing. Beyond providing support and contraction, skeletal muscle also exerts
essential roles in temperature regulation, metabolism, and overall health. As the primary reservoir for amino acids, skeletal
muscle regulates whole-body protein and glucose metabolism by providing substrate for protein synthesis and supporting
hepatic gluconeogenesis during illness and starvation. Overall, greater muscle mass is linked to greater insulin sensitivity
and glucose disposal, strength, power, and longevity. In contrast, low muscle mass correlates with dysmetabolism,
dysmobility, and poor survival. Muscle mass is highly plastic, appropriate to its role as reservoir, and subject to striking
genetic control. Defining mechanisms of muscle growth regulation holds significant promise to find interventions that
promote health and diminish morbidity and mortality after trauma, sepsis, inflammation, and other systemic insults. In this
invited review, we summarize techniques and methods to assess and manipulate muscle size and muscle mass in
experimental systems, including cell culture and rodent models. These approaches have utility for studies of myopenia,
sarcopenia, cachexia, and acute muscle growth or atrophy in the setting of health or injury.
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phenotyping, Skeletal muscleWhat follows is an invited review summarizing a presenta-
tion by Teresa Zimmers in the Master Class Session of the
2018 Annual Meeting of the Shock Society.
INTRODUCTION
Skeletal muscle is a dynamic tissue comprising 40% of the
total mass of a human body. In addition to providing force
production for respiration, eating and locomotion, skeletal
muscle acts as an endocrine organ regulating whole body
metabolism, glucose and lipid metabolism, inflammation,
and even sleep and circadian rhythm (1–3). Muscle-derived
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605(4), and exosomes (5) all exert substantial influence over
adjacent tissues such as bone as well as distant tissues including
liver, adipose and the pancreas. Muscle also represents an
energy repository and storehouse of amino acids and nitrogen
which is liberated during states of acute infection, injury and
starvation (6–8). Increased muscle mass and muscle quality are
associated with better outcomes and prognoses across disease
conditions, while muscle loss is associated with poor outcomes
and increased mortality (9–13). Moreover, products of muscle
destruction can precipitate coagulation and kidney function and
injury (14).
Skeletal muscle mass and quality is a powerful modulator of
morbidity and mortality in health and disease, including sepsis,
shock, burns and trauma. Myopenia at injury is associated with
poor outcomes, demonstrating the need for adequate skeletal
muscle at baseline. Furthermore, injury induces muscle wast-
ing, often both in the acute injury period and in the longer term.
This muscle loss and accompanying muscle dysfunction often
lead to dysmobility, asthenia, disability, and ultimately, death
(Fig. 1). Thus, assessment of skeletal muscle mass, quality, and
regulation of muscle growth and wasting are important for
understanding systemic disease conditions and for predicting
patient outcomes.
Discovery of mediators of muscle growth regulation requires
responsive experimental systems and methods to quantify
muscle size and mass. Given the conservation of many growth
regulatory pathways and the food production value of muscle,
FIG. 1. Overview of this invited review. Trauma leads to a systemic inflammatory response syndrome (SIRS) and shock, which producesmediators that act
on muscle to produce atrophy through effects on multiple processes affecting the myofibers but also the motor neurons. This leads to morbidity and mortality. We
review methods to interrogate the mechanisms underlying this injury-induced atrophy using cell culture, mouse models, and available datasets. CT indicates
computed tomography; DXA, dual energy x-ray absorptiometry, PSR, picrosirius red; SDH, succinate dehydrogenase; TLR, toll-like receptor.
606 SHOCK VOL. 53, No. 5 RUPERT ET AL.multiple model organisms and a variety of species have been
studied, ranging from worms, flies, and fish (zebrafish as well
as salmon), to rodents, ruminants, and pigs. Here, however, we
will focus on cell culture of mouse and human muscle cells, as
well as on the use of mouse models and available cell, murine,
and human data given their predominance in the biomedical
literature. In this invited review, we provide an overview of
in vitro, in vivo, and in silico methods to probe muscle growth
and wasting in the setting of normal biology or in the presence
of trauma, burn, sepsis, inflammation, or other injury relevant
to the readers of Shock (Fig. 1).IN VITRO ASSESSMENT OF MUSCLE SIZE
REGULATION
C2C12 myogenesis
Skeletal muscle myogenesis, muscle growth, and muscle
atrophy can be investigated in culture using myoblast cell lines,
primary cells, and isolated myofibers. The C2C12 murine
myoblast cell line is a well-established, readily accessible
in vitro model for assaying potential regulators of muscle
differentiation and muscle growth (15). These immortalized
myoblasts can be passaged as mononuclear cells in conditions
of growth factor abundance (growth medium or GM: DMEM
with 10–20% fetal calf serum), but when washed and placed in
restricted growth factor conditions (differentiation medium or
DM: DMEM with 2% donor horse serum), the cells express
myogenin, withdraw from the cell cycle and express Cdkn1a/
p21, then progressively fuse and express contractile proteins,
resulting in long, multi-nucleated myotubes (Fig. 2A). Detailed
protocols for generating and visualizing myotubes have been
described previously (16).
Under ideal conditions, myoblasts will fully fuse into
multinucleated myotubes 4 to 5 days after transfer intoDM, producing striking patterns of striated and often visibly
contracting myotubes (Fig. 2B). Growth of these myotubes,
as growth of myofibers, is the result of both accretion of
nuclei from newly fused and differentiating myoblasts and of
protein synthesis and resulting cellular hypertrophy. Effects
of nuclear accretion can be eliminated after a point by
treating cultures with antiproliferative agents such as arabi-
nosylcytosine (AraC; Sigma) to kill myoblasts, leaving a
purer culture of myotubes. Often this is done by transferring
myotubes from DM to GM with AraC for 48 h and then back
to DM for 24 h for recovery. Whether myoblasts are depleted
or not, once myotubes are well differentiated, agents specific
to an hypothesis (e.g., drugs, cytokines, lipids, exosomes,
tumor cell conditioned media, mouse or human serum/
plasma, etc.) can be added to the differentiation media
and effects on myotube diameter can be assessed. Further-
more, therapeutic interventions in combination with atrophy
inducing agents can be used to treat myotubes to evaluate the
efficacy of an intervention to maintain or increase
myotube size.
Myotube morphometry
Myotubes can be visualized via phase contrast or bright field
microscopy without staining, or by staining with Ponceau S
(17) or Cresyl violet. To readily distinguish myotubes from
unfused cells however, observers often use immunofluores-
cence for myosin heavy chain (MyHC) to highlight cell bodies
and DAPI to visualize nuclei (18). Fluorescent myotubes and
nuclei are then imaged using a camera-equipped fluorescence
microscope or plate scanner in such a manner as to ensure
equivalent sampling of wells. This can be done by photograph-
ing the entire well or by sampling the same regions within each
well across experimental conditions. Note that the center and
edges of the wells will have greater and lesser density of
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FIG. 2. Assessing effects on muscle size using C2C12 myotube cultures. A, Schematic of a typical C2C12 differentiation study in which myoblasts are
grown in fetal calf serum-containing growthmedia, then washed and switched to low growth factor containing differentiationmedia (DM) for 4 days, then incubated
with test factors for 48 h, then washed, fixed, and measured on day 8. B, Myotubes are visualized by immunofluorescence with antimyosin heavy chain antibody
(green) and DAPI to visualize nuclei (blue). C, Manual measurements on calibrated micrografts can be done manually using ImageJ. D, Alternatively, wells can be
scanned on digital scanning microscopes (Lionheart was used here), and E, automated image analysis used to determine total area covered by myotubes (object
sum area), the number of nuclei within myotubes (fused nuclei), and the ratio. Here 4-day-old myotubes were incubated for 48h in 100%DM or 50% DMwith 50%
pancreatic cancer cell conditioned media (PC-CM) or 100% PC-CM. Automated imaging demonstrates a reduction in overall green area, a non-significant
reduction in fused nuclei, and reductions in the ratio, indicating smaller myotube cell body size per nucleus or atrophy. *P<0.05; ****P<0.0001. These studieswere
done using four replicate wells per condition.
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sampling images.
Appropriate constraints should be specified a priori and
could include measurement of only myotubes that stain positive
for MyHC or other muscle markers such as dystrophin, that are
fully in frame, and that contain a minimum number of nuclei
(variously specified in the literature as 2 to 10). Myotube
measurements should be done away from nuclear accretions
and should be standardized across conditions. Myotube diam-
eter and fusion index can be measured either manually from
micrographs using opensource software programs such asImage J (Fig. 2C) or automatically using scanning digital
microscopes such as the Incucyte, Lionheart (Biotek), or
similar product. While segmentation and measurement of
individual myotubes is difficult with automated systems, gen-
erally proprietary software can estimate differences across
wells by measuring total green area as a marker of total MyHC
presence/total myotube area, and fusion index by determining
the number of DAPI-positive nuclei within the green area
(Figs. 2D, E). The automated assessment of myotubes across
wells is useful with higher throughput experiments (e.g.,
screening compound libraries) to detect differences across
608 SHOCK VOL. 53, No. 5 RUPERT ET AL.wells in up to 48-well plates. Effects detected by automated
analysis can subsequently be confirmed independently via
manual measurements.
Experimental considerations
Controls are useful when assaying novel conditions for
effects on myotube size. Positive controls for hypertrophy
could include a hypertrophic stimulus leading to enhanced
protein synthesis, such as addition of recombinant IGF-1 (long
IGF) (19, 20), which ultimately activates AKT, or transfection/
infection with constructs to express constitutively activated
AKT. Positive controls for atrophy could include use of glu-
cose-depleted differentiation medium, or addition of glucocor-
ticoids (20, 21) or other atrophy-inducing stimuli including
LPS plus INF-g (17), myostatin, TNF, or Interleukin-6 (22).
Myotube experiments are also useful for investigating molecu-
lar changes associated with muscle atrophy and hypertrophy.
Using the same culture approach as described, alongside wells
meant for imaging, wells of myotubes can processed to collect
media, exosomes, and cellular DNA, RNA and protein for
various downstream analyses. In this fashion, markers of
hypertrophy could be quantified using as puromycin incorpo-
ration into nascent proteins and detection by Western blotting
analysis, or by total protein or total muscle specific protein.
Similarly, one could assay markers of muscle proteolysis such
as total protein ubiquitylation by Western blotting analysis or
RNA expression of muscle-specific ubiquitin ligases MAFbx/
Atrogin-1/Fbxo32, Murf-1/Trim63 (23), or others such as
MUSA1 and SMART (24) by quantitative real-time reverse
transcription and PCR (qPCR).
Excellent technique and attention to culture conditions is
important. High-quality studies with C2C12 myotubes require
consistency between experiments, maintaining plating density,
depth of media, regular changes of media, and timepoints of
analysis. The system should be optimized and validated within
each laboratory and by each operator. Morphologic changes can
be benchmarked against myogenic gene expression. Points of
reference are available in multiple published datasets, including
those deposited into the Gene Expression Omnibus as
GSE11415 (6 timepoints from confluence to 5 days (25)),
GSE20059 (6 conditions of differing confluence and differen-
tiation stage (26)), and GSE17039 (26 conditions in early
myogenesis (27)). These can be readily queried using a paid
or free version of Illumina BaseSpace Correlation Engine (28)
or GEO2R (29), the NCBI R-based web application to query
genes of interest along the myogenic course.
During growth conditions, myoblasts must be kept at low
confluence to avoid selecting against cells with differentiation
potential. Well-cared for cell lines should elicit robust differ-
entiation with most of the surface covered with myotubes
(Fig. 2D). Timing is important; effects observed after 4-day
of differentiation might be absent in 7-day cultures, due to
changes in gene expression. The presence or absence of
myoblasts could also influence outcomes and interpretation.
Substantial variation in this system across laboratories is evi-
dent in the literature, a pitfall of this approach. Discrepancies
could be due to specifics of culture conditions, including serum
type (30, 31) and subclone, given the well-recognized variabledifferentiation potential of lines shared among laboratories. As
well, lower passage clones tend to differentiate better than
higher passage lines. Thus, reviewers should demand represen-
tative images from authors and reviewers and readers both
should be cautious of studies that draw conclusions from
cultures of few or sparse myotubes.
Rigor
Rigor is increased with distribution of plating variables
across different plates rather than between plates, with use
of multiple technical replicates, with blinding of the observer to
experimental conditions, and with sampling of several hundred
to a thousand myotubes per condition, determining the average
myotube diameter of each well, and calculating standard
deviations and statistical differences based upon the number
of wells and not on thousands of myotubes. Care should also be
taken to compare equivalent sections of each well, given that
cells can sometimes pool in the center of the well, generating
gradients of cell density and myogenesis. Results should be
repeated at least once in a separate culture experiment.
Alternative cell lines
In addition to the C2C12 line and the similar rat L6 myoblast
cell line, investigators can isolate or purchase primary satellite
cells/myoblasts/muscle progenitor cells for similar myogenesis
studies. Abundant resources describe multiple protocols for the
isolation and culture of primary myoblasts, ranging from
explanting muscle and harvesting of migrating cells to auto-
mated tissue digestion and magnetic selection or flow cytom-
etry approaches. Use of primary satellite cells or myoblasts can
leverage genetically modified mice. Human primary myoblasts
can be purchased from several vendors including Lonza and
Cook Myosite; however, these cell preparations are expensive,
have limited replication potential prior to onset of senescence,
and display variable myogenic potential. Recently, hTERT/
cdk4 immortalized human myogenic cell lines have been
developed, which could greatly facilitate studies of human
myogenesis and muscle growth regulation (32).
In vitro genetic manipulation of muscle size
Muscle mass is remarkably plastic and research over the past
decades has identified key cell autonomous and non-cell auton-
omous pathways regulating hypertrophy and atrophy of skeletal
muscle (33–35). Targeting these pathways has been an area of
interest for the treatment of muscle wasting associated with
various pathologies including cancer, muscular dystrophy, burn
injury, sepsis, and aging (8, 36, 37). Using cultured myotubes to
genetically manipulate muscle size provides an excellent first
screen prior to embarking uponmore costly and time-consuming
invivomethods. Specific genes can be expressed, knocked down,
or knocked out by transfecting myoblasts with cDNA- or
shRNA-expressingplasmids,withRNAs such as siRNA, lnRNA,
miRNA, or with CRISPR constructs using plasmids or gRNAs,
then differentiating the myoblasts into myotubes. (It should be
noted that the potential polyploidy and limited differentiation
potential of C2C12 myoblasts make CRISPR-based approaches
challenging.) Genetic manipulation is generally accomplished
by transfecting myoblasts with plasmids or siRNA using
SHOCK MAY 2020 ASSESSMENT OF MUSCLE SIZE AND MUSCLE GROWTH REGULATION 609Lipofectamine 3000or other transfection reagents or by infecting
myoblastswith lentivirus tomanipulate genes of interest (38, 39).
Transfection of myoblasts can affect their differentiation
potential; however, so proper controls are essential. In theory,
myoblasts could be transfected with an inducible construct,
permitting expression only after differentiation into myotubes;
in practice, such a system is not widely reported.
Differentiated myotubes are notoriously resistant to trans-
fection via conventional means, regardless of transfection
reagent. Physical transfection approaches including particle-
based magnetic and biolistic approaches are generally ineffi-
cient (data not shown and (40)). Electroporation of myotubes
seeded on coverslips has been reported although not widely
adopted (41). Electroporation with an immersion electrode is
efficient but results in copious fusion events, grossly altering
myotube morphology (TAZ, data not shown). Genetic manip-
ulation in myotubes is most efficient and straightforward
through use of viral vectors. Adenovirus readily infects
C2C12 myotubes (22), but for safety of personnel involved
in the preparation and handling of vectors, adeno-associated
viruses are preferred and also highly effective (42). Recombi-
nant adeno-associated viruses readily transduce both dividing
and non-dividing cells and persist as episomal chromatin in
muscle (43), allowing for long-term expression in differentiated
myotubes in vitro and muscle fibers in vivo. A recent study
using AAV6 documents infection of 5-day-old myotubes with
an anti-atrophy gene resulting in resistance to challenge with a
atrophy-inducing stimulus 48 h later (44), demonstrating the
power and utility of this approach.IN VIVO AND EX VIVO ASSESSMENT OF MUSCLE
MASS AND SIZE REGULATION
In vivo measurement of lean mass
Estimation of muscle mass in living mice and rats begins
with whole body weights and is refined by quantitative assess-
ments of whole-body lean mass. Quantitative time domain
nuclear magnetic resonance (qNMR) and dual energy X-ray
absorptiometry (DXA) can also be used to estimate lean body
mass (45). Assessments by qNMR (EchoMRI and Bruker
instruments) can be done on awake animals, while DXA
requires general anesthesia. Although the literature is littered
with reports equating lean mass to muscle mass, neither of these
approaches quantifies skeletal muscle specifically, which
requires quantitative imaging approaches such as micro X-
ray computed tomography (microCT) (46). MicroCT can be
used to segment and measure individual muscle volumes in
mice and rats longitudinally across an experiment; however, the
long times under anesthesia, the complexity of quantitative
image analysis, and the expense and relative rarity of such
systems usually render them impractical for simple assessments
of mass. More typical is the use of euthanasia, dissection and
direct measurement of muscle mass and size in tissues.
Ex vivo measurement of muscle mass
Destructive analysis of muscle mass begins with identifica-
tion, excision, and weighing of individual muscles immediately
post-mortem to determine changes to muscle mass. To accountfor size differences between animals, ex vivomuscle weight can
be normalized to body weight at the beginning of a longitudinal
experiment or to tibia length in most any experiment. Anatomic
maps of mouse skeletal muscles are available (47–49) and
a video demonstrating muscle identification, excision, and
collection is published and available via open access (50).
Fixation of excised muscles
Muscle mass in normal mice is absolutely linked to myofiber
number and myofiber size. In pathological conditions, muscle
mass could be affected by infiltrating immune cells, fatty
change, fibrosis and extracellular matrix expansion, and water
content. Histomorphometry is used to distinguish these. Skele-
tal muscle is high in water content and this must be considered
during the fixation process. Muscle is commonly fixed using
two methods, either with formalin or by freezing. Choice of
fixation is determined by the downstream analyses. Excellent
protocols for formalin fixed, paraffin embedded (FFPE) muscle
preparation, and analysis are widely available, including here
(51). To prevent shrinkage of muscle, isolated muscles or
biopsy specimens are gently pulled to their normal length
using a clamp or by pinning to a wax substrate (e.g., dental
wax sheets). Fixation is performed by submerging tissue (50–
100mg) in formalin for 24 to 72 h, depending on the volume of
the specimen. The tissue is then processed, paraffin embedded
as usual, and sectioned on a microtome. Formalin fixation
cross-links proteins within the tissue, which needs to be
reversed prior to immunohistochemistry using a chemical or
heat-mediated antigen retrieval process, which can be quite
harsh and alter the structure of antigens. Deparaffinization
removes almost all lipids from the sample, leaving empty space
behind. FFPE sections are typically stained with H&E and
provide visualization of invading inflammatory cells, fibrosis,
cell body size, and presence of centrally located nuclei.
Snap freezing and cryosectioning of muscle can be prefera-
ble to paraffin fixation because it eliminates an antigen retrieval
step during immunohistochemistry (IHC), and because freezing
preserves both lipids and protein/enzyme activity. Frozen sec-
tions can be stained with Oil Red O or other lipophilic stain to
reveal extent of myosteatosis (Fig. 3A) and fatty infiltrates,
both of which are frequent markers and potential mediators of
muscle atrophy (52–54). Enzymatic assays including succinate
dehydrogenase (SDH) and nicotinamide adenine dinucleotide
(NADH) reactions can help localize mitochondria and identify
muscle fiber oxidative capacity (Fig. 3B), key mediators of
muscle mass, function, and metabolism (55, 56). Snap freezing
muscle is not trivial and requires some practice to produce
useable specimens. A video demonstrating snap freezing and
sectioning is available online (50). When snap freezing the
muscle, the fascicles must be perpendicular to the disc to obtain
true cross-sectional slices or parallel to the disc to obtain
longitudinal sections. For measurements of muscle fiber size,
muscles must be cryosectioned to the mid-belly, the region of
greatest cross-sectional area. Frozen sections can be stored in
slide boxes wrapped in plastic at 808C until use. Alterna-
tively, for visualizing transgenic GFP or other highly soluble
proteins, frozen sections can be stored overnight in a box
containing formaldehyde-soaked filter paper for vapor phase
FIG. 3. Histological assessment of murine tibialis anterior muscle sections. A, Oil Red O staining of frozen tibialis anterior reveals increased lipid
accumulation in small oxidative fibers versus larger glycolytic fibers. B, Enzymatic staining for succinate dehydrogenase shows light, medium, and strong staining
reflective of the increasing oxidative capacity of each fiber. C, Trichrome staining reveals blue-stained collagen outside fibers. D, Manual measurements of
individual fibers on H&E stained sections using ImageJ. E, Immunofluorescence using antilaminin antibody results in high contrast images suitable for automated
segmentation using an ImageJ macro. F, Results from either manual (white) or automated (black) measurements are highly concordant. G, Immunofluorescence
visualized by Lionheart LX microscope of antidystrophin antibody (red) on tibialis anterior sections. Segmentation (yellow) and quantification in a histogram using
Gen5 software, H. The mice from which the muscles were taken in (D–F) were much younger than those in (G, H), hence the difference in mean fiber size.
610 SHOCK VOL. 53, No. 5 RUPERT ET AL.fixation (57), storing serial sections without fixation to preserve
enzyme activity. Properly stored frozen sections can also be
scraped from slides and used for preparation of DNA, RNA,
or protein.Morphometric analysis of muscle fiber cross-sectional
area (CSA)
Increase or decrease in the average CSA of muscle fibers is
associated with muscle hypertrophy and atrophy respectively.
SHOCK MAY 2020 ASSESSMENT OF MUSCLE SIZE AND MUSCLE GROWTH REGULATION 611Analysis of muscle fiber CSA can be performed on either FFPE
or frozen sections and generally involves staining the tissue
with H&E (Fig. 3D) or performing immunofluorescence using
antidystrophin or antilaminin antibodies (Fig. 3E) to outline the
myofibers. If H&E is used, the resulting images are low contrast
and fiber CSA must be quantified manually using programs
such as Image J (Fig. 3D, right). High contrast images produced
by immunofluorescence permit automated analysis of fiber
CSA using well-described macros and open source software
such as ImageJ (58) (Fig. 3E, right) or CellProfiler (59). Cell
Profiler has also been used to automatically segment and
measure specific fiber types in images obtained by multiplex
IHC. Digital scanning microscopes such as the Lionheart LX
with embedded analysis programs such as Gen5 (Fig. 3G, H)
can also be used to both image and measure myofibers. These
automated methods are an order of magnitude faster than
manual measurements and allow for a large increase in sample
size (both in fibers and sections) while maintaining a high level
of accuracy (Fig. 3, F–H).
In vivo genetic manipulation of muscle size
Genetic manipulations to assay effects on muscle size are
possible in mice without generation of germline transgenic and
knockout mice. Use of in vivo electroporation permits the
uptake of plasmids and siRNAs, resulting in long-term expres-
sion/repression of the genes of interest (60, 61). To mark
transfected fibers, genes of interests are often co-expressed
with reporter genes, marked with reporter tags, or are co-
electroporated at a 10:1 ratio with reporter plasmids. Common
reporters include TdTomato, mCherry, EGFP and YFP. Marked
fibers expressing genes of interest are measured against simi-
larly transfected control fibers in the opposite limb. Note that
while electroporation produces little overt injury, gene expres-
sion analyses of electroporated muscle reveal evidence of
cytokine release and local inflammation and thus results should
not be overinterpreted as evidence of muscle growth regulation
in health.
Adeno-associated virus (AAV) is also widely used to
express/repress specific genes in vivo, a technology driven
by gene therapy efforts in congenital myopathies. Previous
studies have identified specific AAV serotypes with high
specificity for skeletal muscle infection (62). Skeletal muscle
specificity is enhanced by using synthetic high expressing,
muscle-specific promoters. While local infection in adult mus-
cle groups can permit either assessment of effects on infected
fibers marked with reporter proteins, or effects on distant
muscles in the case of expression of secreted proteins, infection
of neonates can result in long-term and wide-spread expression,
the effects of which can be assayed in adults. Detailed protocols
for such studies are available (63–66).
Germline transgenic and knockout mouse models are avail-
able for the study of atrophy and hypertrophy in skeletal
muscle. However, the use of conditional knockouts enables
attribution of phenotype to muscle-specific mechanisms.
Genetic recombination for skeletal muscle-specific transgenics
or knockouts typically use the muscle progenitor cell/satellite
cell-specific Pax7 promoters or other muscle-specific pro-
moters including myogenic factor 5 (Myf5), myogenicdifferentiation 1 (Myod1), muscle creatine kinase (MCK),
myosin light chain (MLC), and human alpha-skeletal actin
(HSA)/actin alpha 1 (ACTA1), among others, that are activated
in progressively more committed cells during myogenesis (67–
74). To induce mutations or genes in adult myofibers, many
investigators choose the HSA-Cre transgene, in which the cre-
recombinase is activated by a synthetic estrogen receptor
modulator, tamoxifen, given to the mouse either by injection
or through food and water.
In vivo effects on skeletal muscle size are assessed using
gross muscleweights at euthanasia and at the myofiber level, by
measuring the mean fiber CSA and minimum Feret’s diameter
to eliminate artefact from off-center sections or fibers. Rigor is
enhanced in electroporation and AAVexperiments with the use
of empty vectors or scrambled siRNAs in the contralateral limb.
Rigor in all muscle size studies is increased by use of both
sexes, by separating results by sex, by use of multiple individual
mice per condition/genotype, and by co-housing mice of
different genotypes and treatments to account for cage effects.
Our experience demonstrates that a sample size of 10 mice at
10 weeks of age is sufficient to reliably detect a difference in
muscle mass as small as 10%—the rule of 10 s. Appropriate
statistical analysis of myofiber size requires quantifying the
average myofiber diameter of each individual mouse and SD of
the experimental group and calculating statistics based upon
mouse number rather than myofiber number, a common mis-
take in the literature.IN SILICO ASSESSMENT OF MUSCLE
SIZE REGULATION
Phenotype-genotype analysis
Abundant data relating to muscle growth regulation are
available in online repositories, permitting much in silico
investigation prior to embarking upon wet lab experiments.
Primary phenome data from genetically diverse laboratory
mice measured in multiple laboratories using standardized
protocols, including body weights, lean body mass, and skeletal
muscle morphology traits, are collated in the Mouse Phenome
Database, available at https://phenome.jax.org (75, 76). Pub-
lished instructions and guidance for genetic analysis of specific
phenotypes are available for life span and health span, and these
can be adapted for other phenotype queries (77). Such data
across strains can be the starting point for discovering novel
modulators of muscle mass. However, specific genes and loci
regulating body size and thus potentially muscle growth/wast-
ing can be discovered by querying the International Mouse
Phenotyping Consortium (IMPC) website, available at https://
www.mousephenotype.org. At this writing, IMPC had tested
3,126 genes; none thus far demonstrate abnormal skeletal
muscle mass, although 484 demonstrate abnormal body size.
As well, 19 genetic alterations demonstrate abnormal muscle
contractility and 382 abnormal physical strength in mice. For
characterized genes, one can access lists of significant pheno-
types, primary measurements at single mouse resolution,
expression data and images, and more. Mouse Genome Infor-
matics (MGI) provides integrated genetic, genomic, and bio-
logical data on known mouse genes, largely culled from the
612 SHOCK VOL. 53, No. 5 RUPERT ET AL.published studies (78). Searching the Mammalian Phenotype
Browser tool within MGI for abnormal muscle morphology
returns 2,811 genotypes and 5,529 annotations, including 80
genotypes and annotations related to abnormal muscle weight,
10 of which show increased muscle weight (79).
Transcriptomics
Phenotype data can be followed up by probing gene expres-
sion. The Gene eXpression Database (GXD) leverages existing
datasets and is freely available at www.informatics.jax.org/
expression.shtml. Data localizing or quantifying endogenous
expression across developmental stages, between and within
tissues, and between the sexes can be visualized using GXD.
Detailed explanations and instructions are available at the
website and are frequently updated (80). Similar queries can
be done for single or multiple gene expression, tissue-level
gene expression, and histology of human tissues using Geno-
type-Tissue Expression (GTEx), a resource to study tissue-
specific gene expression available at www.gtexportal.org. Sam-
ples of 54 non-diseased tissues across nearly 1,000 persons
were characterized by whole genome sequencing, whole exome
sequencing, and RNAseq. Sex stratification of expression data
is included and biospecimens are available for request.
All existing cataloged information for any gene or protein
can be readily determined by querying all databases at the
National Center for Biotechnology Information portal at
www.ncbi.nlm.nih.gov. Datasets exhibiting differential expres-
sion of a gene can be identified at the Gene Expression
Omnibus (GEO) Profiles portal at www.ncbi.nlm.nih.gov/geo-
profiles, narrowing the search by including keywords such as
‘‘muscle.’’ These datasets can be further analyzed using addi-
tional GEO tools, including Profile neighbors to find similarly
regulated genes within a bioset.
Another powerful tool for learning about a particular gene
is Illumina BaseSpace Correlation Engine’s (28) QuickView
function, which reveals all available information about a gene
of interest present in this curated searchable dataset. The most
correlated tissues, diseases, pharmacological compounds,
gene perturbations, and omics studies are shown and readily
accessible, providing abundant unbiased data about a gene
of interest. Links to literature and relevant clinical trials
are also posted. Such data can immediately associate a gene
with particular disease conditions, other genes or compounds,
enabling the planning of wet lab and mouse studies.FIG. 4. Example of in silico discovery of a novel gene modulating muscNarrowing analysis to skeletal muscle specifically, the
resource MuscleDB, available at www.muscledb.org, can be
used to determine expression of specific genes of interest in a
wide array of murine skeletal muscle groups, from tongue and
eye to masseter, diaphragm, limb muscles and more, versus
cardiac, or smooth muscle (aorta) (81). The murine datasets
were generated using male C57BL/6J mice; however,
MuscleDB also provides searchable RNAseq data for male
and female soleus and extensor digitoris longum muscles from
rats, as well as miRNA from mice and rats (in beta testing as of
this writing).
Using these resources enables the harvesting of considerable
knowledge about a new gene, which could then be functionally
tested in C2C12 cultures, by electroporation or gene transfer
into mouse models, or through genetically modified mice.
Resources for testing a new gene can be found by searching
GeneCards, www.genecards.org, which is focused on human
genes but contains links for products related to murine ortho-
logs. Availability of ES cells, embryos, mice, or sperm carrying
a mutation or transgene for a particular gene of interest can
be determined by searching the International Mouse Strain
Resource (IMSR) at www.findmice.org (82).
An example of in silico analysis
A search of the IMPC database for genotype-phenotype
relationships related to grip strength identified female-specific
increased grip strength in 1700007K13Rik (human ortholog
C90rf116) homozygous null mice (Fig. 4). MGI identified
multiple targeted alleles and phenotypes from two alleles,
including a lethal phenotype due to severe laterality defects,
suggesting strain effects or effects of specific targeting events.
The NCBI all database portal returned no literature focused on
1700007K13Rik, although the gene is mentioned in the full
text of 13 PubMed Central articles. One Gene link and two
Protein links were provided, along with 1,068 Gene Expression
Omnibus (GEO) profiles. Querying GEO Profiles on
‘‘1700007K13Rik AND muscle’’ revealed 61 profiles, with
Nebulin deficiency identified as the top profile for subgroup
effect in profile GDS5880. Using ‘‘Profile neighbors,’’ the
genes Dhrs7, Usp11, Atat1, and others were found to be highly
co-expressed. BaseSpace Correlation Engine identified highest
expression in expression in skeletal muscle psoas and Fallopian
tube. Searching the most correlated studies for keyword
‘‘skeletal muscle.’’ Correlation Engine further revealed thatle function, 1700007K13Rik.
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of a titin-related muscular dystrophy model (dataset
GSE33157) and in denervated muscle (dataset GSE49826),
among other results. In the denervation dataset, mice
with SMAD4 deletion showed 20.8-fold increased
1700007K13Rik over innervated, while wild-type mice with
denervation showed a 12.5-fold increase. MuscleDB showed
highest expression of 1700007K13Rik in tongue, while GTEx
demonstrated low expression in human skeletal muscle com-
pared with all other tissues except blood. These results suggest
that 1700007K13Rik/C90rf116 could play a role in skeletal
muscle mass or function. GeneCards revealed many commer-
cially available products including siRNAs, vectors, and anti-
bodies for future wet lab studies. Moreover, IMSR revealed 15
available strains or lines, with 11 bearing mutations exclusively
in 1700007K13Rik, including three lines with available sperm
and/or embryos. While the functions of 1700007K13Rik/
C90rf116 remain to be determined, this exercise demonstrates
the utility of in silico analyses preparatory to other testing.SUMMARY
Skeletal muscle mass and quality is a powerful modulator of
morbidity and mortality in health and disease, including sepsis,
shock, burns, and trauma. Robust model systems are available
for the interrogation of molecular mechanisms of skeletal
muscle growth regulation. These systems span in vitro to in
vivo studies that are accessible to most biomedical research
laboratories. In silico studies can provide powerful insights to
plan and interpret gene level data. Ultimately, such studies will
lead to means of promoting muscle growth and muscle health,
improving outcomes and survival in patients.
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